Nipro Corporation (JP:8086)
:8086
Want to see JP:8086 full AI Analyst Report?
8086 Stock Chart & Stats
¥1502.50
-¥11.50(-0.77%)
At close: 4:00 PM EST
¥1502.50
-¥11.50(-0.77%)
Day’s Range― - ―
52-Week Range¥1,230.50 - ¥1,664.00
Previous CloseN/A
Volume329.50K
Average Volume (3M)504.50K
Market Cap
¥259.73B
Enterprise Value¥793.91B
Total Cash (Recent Filing)¥109.97B
Total Debt (Recent Filing)¥642.04B
Price to Earnings (P/E)5.6
Beta0.40
Next Earnings
May 12, 2026EPS Estimate
7.45Next Dividend Ex-DateN/A
Dividend Yield2.03%
Share Statistics
EPS (TTM)66.09
Shares Outstanding171,459,470
10 Day Avg. Volume391,050
30 Day Avg. Volume504,500
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)0.88
Price to Sales (P/S)0.34
P/FCF Ratio-27.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)88.59
Revenue Forecast (FY)¥690.27B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA near-10% year-over-year revenue increase shows persistent demand across Nipro's medical device and pharma segments. Durable top-line growth supports scaling of manufacturing, long-term customer relationships, and provides a base for margin recovery and reinvestment over the next several quarters.
Recurring Consumables BusinessNipro's exposure to single-use consumables and pharma supply components generates recurring revenue and stickiness with hospitals and dialysis providers. This structural demand and customer standardization reduce revenue volatility and support predictable medium-term cash flows and market share stability.
Strong Operating Cash GenerationRobust operating cash relative to reported earnings indicates underlying cash-generative operations and good receivables/inventory management. This strengthens resilience to earnings volatility, funds working capital needs, and provides a base for continued investment or debt servicing over the next several quarters.
Bears Say
High Financial LeverageElevated leverage reduces financial flexibility, raises interest and refinancing risk, and constrains strategic options like M&A or capex if margins weaken. In a capital-intensive medical supply business, high debt levels can pressurize liquidity and increase vulnerability to cyclical or operational shocks.
Negative Free Cash FlowPersistently negative free cash flow means the company must rely on financing or asset adjustments to fund growth and dividends. This limits ability to deleverage or invest autonomously and raises the risk that capital projects or margin recovery may be delayed if external funding tightens.
Declining Net Profit MarginA meaningful drop in net income compresses profitability despite stable gross margins, pointing to higher operating costs, SG&A, or non-operating charges. Sustained margin erosion undermines return on equity, reduces internal funding capacity, and complicates long-term margin recovery plans.
Nipro News
8086 FAQ
What was Nipro Corporation’s price range in the past 12 months?
Nipro Corporation lowest stock price was ¥1230.50 and its highest was ¥1664.00 in the past 12 months.
What is Nipro Corporation’s market cap?
Nipro Corporation’s market cap is ¥259.73B.
When is Nipro Corporation’s upcoming earnings report date?
Nipro Corporation’s upcoming earnings report date is May 12, 2026 which is in 19 days.
How were Nipro Corporation’s earnings last quarter?
Nipro Corporation released its earnings results on Feb 09, 2026. The company reported ¥66.09 earnings per share for the quarter, beating the consensus estimate of ¥30.301 by ¥35.789.
Is Nipro Corporation overvalued?
According to Wall Street analysts Nipro Corporation’s price is currently Overvalued.
Does Nipro Corporation pay dividends?
Nipro Corporation pays a Semiannually dividend of ¥18 which represents an annual dividend yield of 2.03%. See more information on Nipro Corporation dividends here
What is Nipro Corporation’s EPS estimate?
Nipro Corporation’s EPS estimate is 7.45.
How many shares outstanding does Nipro Corporation have?
Nipro Corporation has 171,459,470 shares outstanding.
What happened to Nipro Corporation’s price movement after its last earnings report?
Nipro Corporation reported an EPS of ¥66.09 in its last earnings report, beating expectations of ¥30.301. Following the earnings report the stock price went up 0.242%.
Which hedge fund is a major shareholder of Nipro Corporation?
Currently, no hedge funds are holding shares in JP:8086
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nipro Corporation
Nipro Corporation (8086) is a global healthcare company headquartered in Japan, specializing in the development and manufacturing of medical devices, pharmaceuticals, and biotechnology. The company operates primarily in the areas of renal care, intravenous (IV) therapy, and blood transfusion, offering a wide range of products such as dialysis equipment, infusion systems, and various medical disposables. Nipro is committed to enhancing patient outcomes through innovative technologies and high-quality healthcare solutions.
Technical Analysis
Options Prices
Currently, No data available
---